[1] Peyrone, M. Ueber die Einwirkung des Ammoniaks auf Platinchlorür. Ann. Chem. Pharm. 1844, 51, 1.
[2] Werner, A. Beitrag zur Konstitution anorganischer Verbindungen. Z. Anorg. Chem. 1893, 3, 267. [3] Rosenberg, B.; Vancamp, L. Platinum Compounds: a New Class of Potent Antitumour Agents. Nature 1969, 222, 385–386.
[4] Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur. J. Cancer 1998, 34, 1522–1534.
[5] Cleare, M. J.; Hoeschele, J. D. Anti-tumour Platinum Compounds. Relationship between Structure and Activity. Plat. Met. Rev. 1973, 17, 3.
[6] Cleare, M. J.; Hoeschele, J. D. Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes. Bioinorg. Chem. 1973, 2, 187.
[7] Jamieson, E. R.; Lippard, S. J. Structure, Recognition, and Processing of CisplatinDNA Adducts. Chem. Rev. 1999, 99, 2467–2498.
[8] Previati, M.; Lanzoni, I.; Corbacella, E. RNA expression induced by cisplatin in an organ of Corti-derived immortalized cell line. Hear. Res. 2004, 196, 8–18.
[9] Simpson, P. V.; Desai, N. M.; Casari, I. Metal-based antitumor compounds: Beyond cisplatin. Future Med. Chem. 2019, 11, 119–135.
[10] Lazarevic, T.; Rilak, A.; Bugarcic, Z. D. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. Eur. J. Med. Chem. 2017, 142, 8–31.
[11] Kasparkova, J.; Vojtiskova, M.; Natile, G. Unique Properties of DNA Interstrand Cross-Links of Antitumor Oxaliplatin and the Effect of Chirality of the Carrier Ligand. Chem.-Eur. J. 2008, 14, 1330– 1341.
[12] Sigel, A.; Riddell, I. A.; Lippard, S. J. Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions. Met. Ions Life 2018, 1–42.
[13] Arany, I.; Safirstein, R. L. Cisplatin Nephrotoxicity. Semin. Nephrol. 2003, 23, 460–464.
[14] Smith, B. D.; Smith, G. L.; Hurria, A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 2009, 27, 2758–2765.
[15] Duan, Z.; Cai, G.; Li, J. Cisplatin-induced renal toxicity in elderly people. Ther. Adv. Med. Oncol. 2020, 12, 1758835920923430.
[16] Higuchi, K.; Yanagawa, T. Evaluating dose of cisplatin responsible for causing nephrotoxicity. PLoS One 2019, 14, e0215757.
[17] Dana, R.; Kachhwaha, V. S. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity. Indian. J. Cancer 1997, 33, 168–170.
[18] Li, Q.; Guo, D.; Dong, Z. Ondansetron Can Enhance Cisplatin- Induced Nephrotoxicity via Inhibition of Multiple Toxin and Extrusion Proteins (MATEs). Toxicol. Appl. Pharm. 2013, 273, 100–109.
[19] Un, H. R.; Ugan, R. A.; Kose, D. A novel effect of Aprepitant: Protection for cisplatin-induced nephrotoxicity and hepatotoxicity. Eur. J. Pharmacol. 2020, 880, 9.
[20] Abdel-Daim, M. M.; Mahmoud, O. M.; Al Badawi, M. H. Protective effects ofCitrus limoniaoil against cisplatin-induced nephrotoxicity. Environ. Sci. Pollut. Res. 2020, 11.
[21] Li, C.; Li, L. P.; Yi, Y. D. L-tetrahydropalmatine attenuates cisplatin- induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy. Biochem. Pharmacol. 2020, 177, 11. [22] Khalifa, E. A.; Ahmed, A. N.; Hashem, K. S. Therapeutic Effects of the Combination of Alpha-Lipoic Acid (ALA) and Coenzyme Q10 (CoQ10) on Cisplatin-Induced Nephrotoxicity. Int. J. Inflamm. 2020, 2020, 11.
[23] Kolinsky, D. C.; Hayashi, S. S.; Karzon, R. Late Onset Hearing Loss: A Significant Complication of Cancer Survivors Treated With Cisplatin Containing Chemotherapy Regimens. J. Pediat. Hematol. Onc. 2010, 32, 119.
[24] Gentilin, E.; Simoni, E.; Candito, M. Cisplatin-Induced Ototoxicity: Updates on Molecular Targets. Trends Mol. Med. 2019, 25, 1123–1132.
[25] Turan, C.; Kantar, M.; Aktan, C. Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1. Cancer Chemother. Pharmacol. 2019, 84, 1333–1338.
[26] Rademaker-Lakhai, J. M. Relationship between cisplatin administration and the development of ototoxicity. J. Clin. Oncol. 2006, 24, 918.
[27] Oh, S. H.; Yu, W. S.; Song, B. H. Expression of Heat Shock Protein 72 in Rat Cochlea with Cisplatin-induced Acute Ototoxicity. Acta Oto-Laryngol. 2000, 120, 146–150.
[28] Rybak, L. P.; Whitworth C.; Somani, S. Application of Antioxidants and Other Agents to Prevent Cisplatin Ototoxicity. Laryngoscope 2010, 109, 1740–1744.
[29] Di, Y.; Xu, T.; Tian, Y. Ursolic acid protects against cisplatin- induced ototoxicity by inhibiting oxidative stress and TRPV1- mediated Ca2+-signaling. Int. J. Mol. Med. 2020, 46, 806–816.
[30] Lee, H. S.; Kim, Y. R.; Lee, I. K. KL1333, a derivative of beta- lapachone, protects against cisplatin-induced ototoxicity in mouse cochlear cultures. Biomed. Pharmacother. 2020, 126, 6.
[31] Lee, C. H.; Lee, D. H.; Lee, S. M. Otoprotective Effects of Zingerone on Cisplatin-Induced Ototoxicity. Int. J. Mol. Sci. 2020, 21, 11.
[32] Somdas, M. A.; Gunturk, I.; Balcioglu, E. Protective effect of N-acetylcysteine against cisplatin ototoxicity in rats: a study with hearing tests and scanning electron microscopy. Braz. J. Otorhinolaryngol. 2020, 86, 30–37.
[33] Naples, J. G.; Ruckenstein, M. J.; Singh, J. Intratympanic Diltiazem-Chitosan Hydrogel as an Otoprotectant Against Cisplatin-Induced Ototoxicity in a Mouse Model. Otol. Neurotol. 2020, 41, 115–122.
[34] Paciello, F.; Rita Fetoni, A.; Mezzogori, D. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci. Rep. 2020, 10, 1063.
[35] Santos, N.; Ferreira, R. S.; Santos, A. C. D. Overview of cisplatin- induced neurotoxicity and ototoxicity, and the protective agents. Food Chem. Toxicol. 2020, 136, 111079.
[36] Troy, L.; McFarland, K.; Littman-Power, S. Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-Oncol. 2000, 9, 29.
[37] Fischer, D.; Malik, T. Chemotherapy-Induced Peripheral Neuropathy. In Practical Chronic Pain Management: A Case-Based Approach. Ed.: Malik, T., Springer International Publishing, 2020, pp. 371–380.
[38] Qi, L.; Luo, Q.; Zhang, Y. Advances in Toxicological Research of the Anticancer Drug Cisplatin. Chem. Res. Toxicol. 2019, 32, 1469–1486.
[39] Podratz, J. L.; Tang, J. J.; Polzin, M. J. Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity. Exp. Neurol. 2020, 331, 113376.
[40] Kandeil, M. A.; Mahmoud, M. O.; Abdel-Razik, A. R. H. Thymoquinone and geraniol alleviate cisplatin-induced neurotoxicity in rats through downregulating the p38 MAPK/STAT-1 pathway and oxidative stress. Life Sci. 2019, 228, 145–151.
[41] Ferreira, R. S.; dos Santos, N. A. G.; Bernardes, C. P. Caffeic Acid Phenethyl Ester (CAPE) Protects PC12 Cells Against Cisplatin-Induced Neurotoxicity by Activating the AMPK/SIRT1, MAPK/Erk, and PI3k/Akt Signaling Pathways. Neurotox. Res. 2019, 36, 175–192.
[42] N S, V.; Mohamad, A.; Razdan, R. Allantoin attenuates deficits of behavioural and motor nerve conduction in an animal model of cisplatin-induced neurotoxicity in rats. Anim. Models Exp. Med. 2019, 2, 114–120.
[43] Li, Y. X.; Zheng, M. Y.; Sah, S. K. Neuroprotective influence of sitagliptin against cisplatin-induced neurotoxicity, biochemical and behavioral alterations in Wistar rats. Mol. Cell. Biochem. 2019, 455, 91–97.
[44] Khadrawy, Y. A.; Ei-Gizawy, M. M.; Sorour, S. M. Effect of curcumin nanoparticles on the cisplatin-induced neurotoxicity in rat. Drug Chem. Toxicol. 2019, 42, 194–202.
[45] Rosic, G.; Joksimovic, J.; Selakovic, D. The Beneficial Effects of Sulfur-containing Amino Acids on Cisplatin-induced Cardiotoxicity and Neurotoxicity in Rodents. Curr. Med. Chem. 2018, 25, 391–403.
[46] Cubeddu, L. X.; Hoffmann, I. S.; Fuenmayor, N. T.; Finn, A. L. Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting. New Eng. J. Med. 1990, 322, 810–816.
[47] Li, G.; Zhang, Q.; Du, J. Effect of XBXT on Prevention and Treatment of Gastrointestinal Tract Inflammation Injury Induced by Cisplatin in Rats. Traditional Chinese Drug Research & Clinical Plarmacology 2017, 28, 459–463.
[48] Yilmaz, Y.; Tumkaya, L.; Mercantepe, T. Protective effect of astaxanthin against cisplatin-induced gastrointestinal toxicity in rats. Eur. Surg. 2020, 7.
[49] Hyun, L. The Effects of Dokhwaljihwang-tang Intravenous Pharmacopuncture on Cisplatin-Induced Emesis and Gastrointestinal Mobility Disorder in Rats. J. Acupunct. Res. 2017, 34, 39–48.
[50] Cai, Y.; Wu, Y.; Ye, F. Moxa salt packets at Zhongwan (CV 12) for cisplatin chemotherapy-induced gastrointestinal reactions: a clinical study. Chinese Acupuncture & Moxibustion 2016, 36, 405–408.
[51] Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Update 2005, 8, 131–146.
[52] Amable, L. Cisplatin resistance and opportunities for precision medicine. Pharmacol. Res. 2016, 106, 27–36.
[53] Hall, M. D.; Okabe, M.; Shen, D.-W. The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 495–535.
[54] Jamalia, B.; Nakhjavani, M.; Hosseinzadeh, L. Intracellular GSH Alterations and Its Relationship to Level of Resistance following Exposure to Cisplatin in Cancer Cells. Iran. J. Pharm. Res. 2015, 14, 513–519.
[55] Wan, W. F.; Sun, J. J.; Liu, W. R. Reductions of the cisplatin-based platinum(IV) prodrug cis, cis, trans-Pt(NH3)2Cl2Br2 by predominant biological thiols: kinetic and mechanistic studies. Transit. Met. Chem. 2019, 44, 535–544.
[56] Kama, N. S.; Soria, J. C.; Mendiboure, J. MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer. Clin. Cancer Res. 2010, 16, 1206.
[57] Bassett, E.; Vaisman, A.; Tropea, K. A.Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases β and η DNA Repair 2002, 1, 1003.
[58] Shachar, S.; Ziv, O.; Avkin, S. Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. EMBO J. 2009, 28, 383.
[59] Rocha, C. R. R.; Silva, M. M.; Quinet, A. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics 2018, 73, e478s.
[60] Martin, L. P.; Hamilton, T. C.; Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14, 1291–1295.
[61] McNeil, E. M.; Astell, K. R.; Ritchie, A.-M. Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair 2015, 31, 19–28.
[62] Kelley, M. R.; Logsdon, D.; Fishel, M. L. Targeting DNA repair pathways for cancer treatment: what’s new? Future Oncol. 2014, 10, 1215–1237.
[63] Vendetti, F. P.; Lau, A.; Schamus, S. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 2015, 6, 44289–44305.
[64] Albarakati, N.; Abdel-Fatah, T. M. A.; Doherty, R. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol. Oncol. 2015, 9, 204–217.
[65] Alagpulinsa, D. A.; Ayyadevara, S.; Shmookler Reis, R. J. A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin. Front. Oncol. 2014, 4.
[66] Sail, V.; Rizzo, A. A.; Chatterjee, N. Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction. ACS Chem. Biol. 2017, 12, 1903–1912. |